Anti-Jo-1 antibodies (AJoA), which bind to and inhibit the activity of histidyl-transfer RNA synthetase (HRS), are found in a genetically and clinically distinct subset of myositis patients. This specificity suggests that understanding the antigenic epitopes and immunoregulation governing the production of AJoA may result in clues to disease pathogenesis. Limited digestion of human HRS by V8 protease resulted in four major antigenic polypeptides of 35, 34, 21, and 20 kD; digestion with subtilisin gave four fragments of the same sizes and two additional major antigenic polypeptides of 28 and 17 kD. Sera from 12 AJoA positive patients reacted indistinguishably with these proteolytic fragments by Western blotting, and AJoA elution studies suggested a common epitope(s) on all six. Isoelectric focusing showed a different polyclonal pattern of AJoA in each patient, although serial analyses in individual patients revealed stable AJoA spectrotypes over years of observation. Enzymelinked immunosorbant assays showed that the AJoA response was mainly restricted to the IgG1 heavy chain isotype. The levels of IgG1 AJoA varied in proportion to disease activity over time but were independent of total IgG1 levels, and three patients became AJoA negative as their myositis remitted after treatment. These findings suggest that AJoA are induced by an antigen-driven mechanism, bind to a common epitope or epitopes on HRS, and are modulated by an immune response closely linked to that which is responsible for myositis in these patients. (J. Clin. Invest. 1990. 85:468-475.) anti-histidyltRNA synthetase * autoantibody subclass * dermatomyositisi immunomodulation * polymyositis
identified tRNAs (6) , elongation factors (6) (7) (8) , and the signal recognition particle (9) . The autoantigen to which myositis autoantibodies are most frequently directed is histidyl-tRNA synthetase, also known as Jo-i antigen, which catalyzes the esterification of histidine to its cognate tRNA (1) . Patients who develop anti-Jo-I antibodies (AJoA) are a genetically restricted group (10) with a high incidence of interstitial lung disease, arthritis, and Raynaud's phenomenon (1 1) . AJoA are seen in -33% of patients with primary polymyositis, 25% with primary dermatomyositis, and 15% with myositis associated with another connective tissue disease, and have not been detected in other subgroups of patients with idiopathic inflammatory myopathy (12) . Patients with AJoA also tend to be younger with an acute onset of myositis in the first half of the year (13) .
The reasons for the remarkable association of these autoantibodies with certain forms of myositis are unknown. It has been suggested, however, that they might arise as a result ofthe interaction of translational components with infecting positive-stranded RNA viruses, notably picornaviruses (1) , which are also associated with myositis through ultrastructural (14) , serological (15, 16) , animal model (17) (18) (19) , and complementary nucleic acid hybridization studies (20) .
The role of AJoA in the pathogenesis of inflammatory myopathy remains speculative, yet the high specificity of these autoantibodies for the diagnosis of myositis and the closely associated clinical features and human leukocyte antigen markers suggest that the immunoregulation of AJoA is closely linked to genetic and/or environmental factors responsible for the development of muscle inflammation.
In order to understand the in vivo induction and regulation of the production of these unique autoantibodies, we have studied their antigenic epitopes, spectrotypes, class and subclass distribution, as well as the variation in their levels, in a population of well-characterized myositis patients followed over a long period of time. Our data show that AJoA from all patients appear to react with a common epitope or epitopes on HRS. Additionally, we found stable polyclonality ofthe AJoA response, in spite of its marked isotype restriction to IgG1, and correlation of AJoA levels with myositis disease activity.
Methods
Sera. All myositis sera were obtained from patients with definite polymyositis or dermatomyositis (21) and were stored at -200C before use. AJoA positive sera were initially identified by double immunodiffusion assays using prototype AJoA positive sera (1) and were confirmed by inhibition of histidyl-tRNA synthetase activity (12 (22) , which were then blocked with 109%o goat serum in borate-buffered saline (GBBS), and incubated with patient serum samples diluted 1:10 in GBBS overnight at 4VC. The sheets were washed with PBS containing 0.05% Tween 20 (PBST), and then incubated with peroxidase-conjugated affinity-purified goat anti-human IgG (Jackson Immunoresearch Laboratories, Avondale, PA) and developed as previously described (22) .
To assess the relationship and complexity of epitopes on the major proteolytic fragments of HRS, we eluted AJoA from the major bands and reprobed other nitrocellulose strips containing all the proteolytic polypeptides. For these experiments, proteolytic fragments of HRS were localized on nitrocellulose sheets using AJoA positive serum and affinity-purified "25I-protein A (Amersham Corp., Arlington Heights, IL) following the manufacturer's specifications. The bands of interest were cut out and AJoA were eluted by washing twice, 10 min each, with a buffer containing 500 mM NaCI, 0.5% Tween 20, 100 ug/ml immunoglobulin-free bovine serum albumin (BSA) (Sigma Chemical Co., St. Louis, MO), 50 mM glycine, pH 2.3. Eluted AJoA were neutralized in 50 mM NaHPO4, pH 7.5, and applied to selected nitrocellulose strips containing proteolytic fragments of HRS that had been previously blocked with BSA. The strips were washed in PBST, incubated with a 1:1,000 dilution of '25I-protein A in 2% BSA for 2 h at room temperature, rewashed, and then processed for autoradiography.
Spectrotype analysis ofAJoA. Isoelectric focusing and nitrocellulose blotting was performed by the method ofKnisley and Rodkey (24) using precast gels (pH 3.5-9.5; Pharmacia LKB Biotechnology, Piscataway, NJ). Sera were diluted 1:5 to 1:25, depending on the AJoA concentration, with 0.015 M borate-buffered saline containing 10% sucrose, 0.5% Tween 20, and 2% ampholines (pH 3.5-9.5; Pharmacia LKB Biotechnology) and 10 Ml was applied to LKB sample template strips placed near the anode. Isoelectric focusing was performed on 10 cm X 10cm gels with cooling (4°C) at 100 V for 15 Hill, NC) to confirm the specificity of the assays. Cross-reactivity to unrelated immunoglobulin classes and subclasses was determined to be < 1.5% in all assays (26, and data not shown).
Class and subclass AJoA quantitations were accomplished using a modification of an AJoA-specific ELISA (12) with human HRS as antigen (22) . IgA and IgM AJoA determinations were performed by incubating microtiter wells (Immulon I plates; Dynatech Laboratories, Alexandria, VA) with 100 Ml of antigen at 2.5 Mg/ml overnight at 40C. Wells into which standards were to be placed remained empty. All other steps were carried out at room temperature and, except where noted, 100 ,l of reagent or sample was used. The next day the plates were washed with PBST and each well, except those into which standards were to be placed, was blocked with 200 Ml of 1% BSA in PBS (PBS/BSA) for I h. After washing the plates in PBST, human IgA or IgM standards, or AJoA positive sera in appropriate dilutions in PBS/ BSA, were added in duplicate to the plates and incubated for 2 h. The plates were washed again with PBST, followed by distilled water, and alkaline phosphatase labeled goat anti-human class-or subclass-specific antibodies, diluted 1:1,000 in PBS/BSA, were added to the plates. After incubation for 2 h, plates were washed with PBST and then distilled water, developed using a phosphatase substrate system (Kirkegaard and Perry Laboratories Inc., Gaithersburg, MD), and read at 410 nm at appropriate time points using a microplate reader (Dynatech, model MR 700). The data were analyzed by the Immunosoft program (Dynatech). Correlation coefficients of the standard curves exceeded 0.97 for each assay and data was calculated only from samples from which absorbance readings fell within the linear portion of the standard curves. IgG subclass AJoA determinations were performed similarly, using the human IgG subclass monoclonal ELISA kit (ICN Immunobiologicals) according to the manufacturer's instructions except for the substitution of antigen for coating antibody as the first step.
Protein sequence analysis. Amino acid sequence analysis ofhuman HRS (27) was performed using the programs ANTIGEN and FLEX-PRO and comparisons of regions for homology were performed using the default parameters of FSTPSCAN (28) on PCGENE (IntelliGenetics, Mountain View, CA).
Data analysis. Statistical analysis ofdata was performed using SAS (SAS Institute Inc., Cary, NC) on an IBM 370 computer. Grouped data were compared by Wilcoxon rank sums and Spearman correlation coefficients were determined using Bonferroni corrections for multiple comparisons (29).
Results
Autoantibodies of a given specificity are characteristically produced by a diversity oflymphocyte clones, yet they often target a common site on an autoantigen molecule. We performed a series of experiments, therefore, to determine the heterogeneity of antigenic epitopes seen by AJoA as well as the complexity and stability of different patients' B cell responses to HRS.
Epitope analyses. When probed with AJoA positive serum by Western blotting, undigested HRS showed two antigenic proteins with apparent molecular sizes of 110 and 55 kD, the former presumably representing undissociated HRS homodimers as previously described (22) . Limited proteolysis of HRS by S. aureus V8 protease reproducibly produced one major, relatively protease resistant, antigenic polypeptide of 35 kD, and three minor polypeptides of 34, 21, and 20 kD. The pattern observed usually included minor bands ofantigenicity trailing the 35-kD fragment and overlapping the 34-kD fragment (Fig. 1 A) in lanes 1-7) . No reaction was seen after incubation with serum from myositis patients containing anti-ribonucleoprotein (8) or anti-La antibodies (9), or with myositis patient serum without antibodies to extractable nuclear antigens (10) , and normal control serum (1 1).
major antigenic fragments ofthe same sizes and two additional major polypeptides of 28 and 17 kD, with minor bands between these two polypeptides (Fig. 1 B) . Other minor bands, possibly the result of varying degrees of proteolysis from sample to sample, were occasionally observed after protease digestion. Prolonged digestion with increased amounts of protease resulted in the complete loss ofall antigenic polypeptides. Sera from all 12 AJoA positive patients tested reacted indistinguishably with the major proteolytic fragments of HRS in each experiment, and no sera from normal controls nor from patients without AJoA recognized any of these polypeptides (Fig. 1) .
In order to assess the relationship and complexity of epitopes on each of the proteolytic fragments, AJoA were eluted from the major polypeptides above and were used to reprobe nitrocellulose strips onto which all proteolytic fragments were blotted. Fig. 2 shows representative results from such an experiment and depicts the common binding of AJoA to all major polypeptides regardless of which fragment was used to elute AJoA. Similar data were obtained from such reprobing experiments after V8 protease digestion of HIRS and from two other AJoA positive patients tested.
In the simplest view, these data suggest that the smaller antigenic polypeptides are generated from the larger ones, that a common epitope or epitopes are present on all the polypeptides, and that AJoA from all positive patients react with this (these) same epitope(s). Analysis of the linear amino acid sequence of human HRS was performed using the PCGENE package to determine whether there are repeated sequences on HRS that could serve as multiple antigenic epitopes. The analysis did not reveal any duplicated regions of greater than four amino acids in length and no regions that were predicted to be similar enough to be related antigenically. We cannot exclude the unlikely possibility, however, that several conformational epitopes exist on the protein that all AJoA see identically.
Spectrotype analysis ofAJoA. To determine the complexity of the AJoA response, we analyzed AJoA spectrotypes by isoelectric focusing sera and allowing AJoA to transfer passively to nitrocellulose sheets previously coated with antigen. All 12 AJoA positive patients' sera studied during active myositis gave positive patterns, whereas normal sera and myositis sera without AJoA gave no detectable bands by this sensitive and specific method (Fig. 3) . Although discrete AJoA bands were often present, all spectrotypes showed a diffuse polyclonal pattern, with each serum having an apparently distinct spectrotype. Fig. 3 Figure 2 . An autoradiograph of a representative immunoblot before (A) and after (B-H) limited digestion of HRS by subtilisin demonstrating that the AJoA binding to intact HRS and to the major antigenic polypeptides (with the position and apparent molecular weight in kilodaltons labeled at the right) can be eluted and will rebind to the other major antigenic polypeptides. A piece of nitrocellulose, on which AJoA from patient 1 were localized by '25I-protein A and prior autoradiography (A-B), was cut into six regions labeled by numbers at the left. AJoA were eluted separately from each of these regions, neutralized and exposed to undeveloped nitrocellulose strips (labeled at the top with a letter corresponding to the region from which AJoA were eluted such that C = 1, D = 2, E = 3, F = 4, G = 5, and H = 6). The smaller HRS antigenic fragments, not well visualized after photographic reproduction, were clearly present on autoradiographs exposed for longer periods of time. Similar data were obtained after repeating this experiment with two other AJoA positive patients and after limited digestion of HRS with S. aureus V8 protease (data not shown).
cases the proportion was less than 1% (Table I) IgGI and total IgG3, r = 0.91. No other significant correlations were found. Given the high specificity of our ELISA assays, these data suggest the possibility of coordinate regulation of several isotypes of both total immunoglobulins and AJoA.
Changes in AJoA levels over time. The analysis of AJoA levels in sera from the 12 patients, who have been followed for periods of 2-13 yr, showed changing IgGI AJoA levels in proportion to changes in myositis disease activity but unrelated to total IgG1 levels. Fig. 4 depicts representative data from four patients and demonstrates the major patterns observed. AJoA levels became undetectable by double immunodiffusion and ELISA assays in 3 of the 12 patients (patients 2, 4, and 10) whose therapy induced the most complete and prolonged remissions of myositis.
Further evidence that IgG1 AJoA levels were proportional to disease activity comes from the analysis of four patients for whom more detailed data were available. During periods of less disease activity, these patients (with clinical activity indices of 0-2) had significantly (P < 0.04 for each) lower AJoA (mean 48 ,g/ml) and serum creatine kinase (CK) levels of myositis patients is remarkable. The origin of AJoA anti-(mean 902 U/liter) than during periods of increased disease bodies has been the subject of a number of hypotheses, all of activity (with activity indices of 3-4, mean IgGI AJoA = 123 which revolve around three "antigen-driven" scenarios. One is ,ug/ml, mean CK = 2,657 U/liter). Analyses of concurrent CK that AJoA result from the direct interaction of the enzyme levels, myositis activity indices and IgG, AJoA levels showed with picornaviral RNA, thereby rendering it "foreign" to the significant correlations among all three (Fig. 5) . host immune system (1) . A second suggests an antiidiotype network is responsible for AJoA, with the portion of viral Discussion RNA which interacts with enzyme being the primary immunogen (31) . A third hypothesis relates to "molecular mimicry" The specificity with which AJoA, which are directed against suggesting that picornaviral proteins may serve as the primary the very sparse and unstable enzyme HRS (30) , are associated immunogen and that regions homologous to the viral proteins with a genetically restricted, clinically distinguished subgroup are present on HRS (32). Our data are consistent with the underlying premise of these hypotheses regarding the role of antigen in the induction and regulation of AJoA. That AJoA are probably antigendriven is supported by the serial appearance of clonally restricted IgM AJoA before IgG, and IgG3 AJoA, all occurring months before myositis onset in a patient observed through the development of myositis (33) , and the complexity and polyclonality of the AJoA immune response as shown by their class and subclass distribution and diffuse spectrotypes in this paper. The antigen-driven nature of AJoA and other autoantibody systems seems inconsistent with hypotheses suggesting that autoimmunity results from generalized (polyclonal) B cell activation (34, 35) , which also occurs in many circumstances not leading to autoimmune disease. Furthermore, generalized B cell stimulation alone would not seem sufficient to explain: (a) the phenomenon of disease-subset specific autoantibodies; (b) the frequent finding of subclass-restricted autoantibodies (36) ; (c) the fact that one does not find autoantibodies to all proteins indiscriminately in autoimmune diseases (37) (in the idiopathic inflammatory myopathies they are directed against a group of cytoplasmic proteins which are often functionally related); (d) the tendency for autoantibodies to target evolutionarily conserved epitopes and to inhibit the function of autoantigens (38) ; and (e) the independent regulation of multiple autoantibodies in the same individual (39, 40) . It is even possible that the apparent polyclonal activation of immunoglobulin-producing cells and the hypergammaglobulinemia observed in some autoimmune conditions represents the result rather than the cause of autoimmunity, perhaps secondary to antigen stimulation and T cell activation (41 (42) . These data in autoantibody systems parallel the pattern observed in standard secondary immune responses to antigens, in which an initial rapid diversification of B cell clones is followed by the maintenance of stable polyclonality (43) (44) (45) (52) .
In other autoantibody systems, however, such as rheumatoid factors (53) , drug-induced anti-histone (52) , anti-thyroid (54), and anti-skin (55) autoantibodies, there appears to be a predominance of IgG4 isotypes; while in others, such as antithyroglobulin (56) , anti-ribosomal P (57), and anti-phosphocholine (58) autoantibodies, IgG2 represents a prominent subclass.
The marked changes in the quantity of AJoA over time appear to reflect changes in myositis disease activity inasmuch as they correlate significantly with serum CK levels and disease activity as judged by the patients' treating physicians. Although these data do not support a pathogenetic role for AJoA, they do suggest that AJoA regulation is closely linked to factors responsible for the disease process in these patients. Many lines of evidence imply that autoimmune phenomena are important as pathologic mechanisms in the idiopathic inflammatory myopathies (59) , and that T cell responses are particularly relevant to disease (60, 61) . If T cells and/or their lymphokines are responsible for modulating both AJoA responses and muscle inflammation, then one might expect to find correlations between the two as a result of interventions known to affect T cells. In fact, all the patients who clinically improved after therapy showed decreases in AJoA levels, and the three patients who experienced prolonged complete remissions, in- duced by oral prednisone and methotrexate or chlorambucil therapy, were the three whose AJoA became undetectable by both ELISA and double immunodiffusion assays. Of these three patients, two have had all medications discontinued and have remained clinically well with no AJoA for up to 4 yr. The finding that patients can change AJoA status from positive to negative as reported here and vice versa (33) also has implications for the appropriate timing of screening for AJoA, which would appear to be best performed during a period of active myositis and before therapy. Further understanding of the factors responsible for AJoA may be obtained from knowledge of the precise antigenic epitopes of HRS. The antigenic polypeptide data presented here, the observation that all AJoA inhibit HRS enzyme activity (12, 62) , and the finding that AJoA do not bind to heat-lenatured HRS (unpublished observations) nor to any hexapeptide of the linear protein sequence (63) , taken together imply that the epitopes are conformational and limited to a small number of functionally critical sites on the molecule. Studies are underway to identify these sites as a further step to understanding the induction of AJoA and idiopathic myositis.
